Resistance rages but antibiotic pipeline is dry
New alarming report from ECDC, EMEA and ReAct presented at EU expert conference
In Europe alone, multi drug-resistant bacteria cause some 25,000 deaths annually while extra costs for healthcare and productivity losses add up to at least €1,5 billion per year. Nevertheless, the R&D pipeline for new drugs is more or less empty. There is, thus, an untenable gap between the burden of antibiotic resistance and the development of new drugs to tackle the problem. This gap is now being addressed by the European Union.
Documentation from the conference